Apixaban for Extended Treatment of Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy and for whom there was clinical equipoise regarding the continuation or cessation of anticoagulation therapy. The study drugs were administered for 12 months. RESULTS: A total of 2486 patients underwent randomization, of whom 2482 were included in the intention-to-treat analyses. Symptomatic recurrent venous thromboembolism or death from venous thromboembolism occurred in 73 of the 829 patients (8.8%) who were receiving placebo, as compared with 14 of the 840 patients (1.7%) who were receiving 2.5 mg of apixaban (a difference of 7.2 percentage points; 95% confidence interval [CI], 5.0 to 9.3) and 14 of the 813 patients (1.7%) who were receiving 5 mg of apixaban (a difference of 7.0 percentage points; 95% CI, 4.9 to 9.1) (P<0.001 for both comparisons). The rates of major bleeding were 0.5% in the placebo group, 0.2% in the 2.5-mg apixaban group, and 0.1% in the 5-mg apixaban group. The rates of clinically relevant nonmajor bleeding were 2.3% in the placebo group, 3.0% in the 2.5-mg apixaban group, and 4.2% in the 5-mg apixaban group. The rate of death from any cause was 1.7% in the placebo group, as compared with 0.8% in the 2.5-mg apixaban group and 0.5% in the 5-mg apixaban group. CONCLUSIONS: Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding. (Funded by Bristol-Myers Squibb and Pfizer; AMPLIFY-EXT ClinicalTrials.gov number, NCT00633893.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For the baseline risk of major bleeding, we used data from 2 randomized trials on people with VTE, showing that the risk of major bleeding with placebo during 18 or 24 months of follow-up was as low as 0.5% 306 and as high as 1.5% in 18 months. 259”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“We identified 2 RCTs 306,314 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“Two of these agents, rivaroxaban and apixaban, have been studied at a reduced dose: from 20 mg daily to 10 mg daily for rivaroxaban and 5 mg to 2.5 mg twice daily for apixaban. 306,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
Citations
Cites
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F., Brady, A. J. B., Ferreira, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn310 · Cited by 2,826
Self-citationApixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationAspirin for Preventing the Recurrence of Venous Thromboembolism
Becattini, C., Agnelli, G., Schenone, A., Eichinger, S., Bucherini, E., Silingardi, M., Bianchi, M., Moia, M., Ageno, W., Vandelli, M. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114238 · Cited by 620
Self-citation
Research works printed but not linked: 1
- Schulman S, 2011, J Thromb Haemost, 9, 22
Cited by
Items 701–800 of 1,000
Lin, Y., Lin, M., Wu, V. C., Chen, Y., Chang, J.-J., Chu, P., Lip, G. Y. H., & Chen, M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.775564 · Cited by 6
Lenchus, J. D., Biehl, M., Cabrera, J. L., de Moraes, A. G., & Dezfulian, C. (2016) · Journal of Intensive Care Medicine · doi:10.1177/0885066616648265 · Cited by 6
Die tiefe Venenthrombose: Diagnostik und Therapie
Wustrow, I., & Ibrahim, T. (2016) · CME · doi:10.1007/s11298-016-5549-x · Cited by 6
Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism
Kimpton, M., & Carrier, M. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1601699 · Cited by 7
“information to patients with acute cancer [51,52].”
Palareti, G., Legnani, C., Antonucci, E., Zorzi, S., Bignamini, A. A., Lodigiani, C., Tosetto, A., Bertù, L., Pengo, V., Testa, S., et al. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02381-5 · Cited by 6
Restarting oral anticoagulants after intracerebral hemorrhage: pros
Ntaios, G. (2014) · Internal and Emergency Medicine · doi:10.1007/s11739-014-1160-x · Cited by 6
“extended treatment of VTE [15–19].”
Beer, J. H., & Bonetti, N. R. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx702 · Cited by 7
Verlängerte Sekundärprophylaxe nach venöser Thromboembolie
Bauersachs, R. M. (2018) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0043-113679 · Cited by 8
“in der reduzierten Prophylaxedosis, da hier bei gleicher Wirksamkeit von einem niedrigeren Blutungsrisiko auszugehen ist [3, 14].”
BackgroundInfluentialScheres, L. J. J., & Middeldorp, S. (2024) · Hematology · doi:10.1182/hematology.2024000593 · Cited by 5
Direct oral anticoagulant failure in patients with venous thromboembolism—why and what next?
Swan, D., Turner, R., Grove, E. L., Schulman, S., & Thachil, J. V. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.03.026 · Cited by 6
Vlazny, D. T., McBane, R. D., Casanegra, A. I., Hodge, D. O., Lang, T. R., Wysokiński, W. E., Peterson, L. G., & Houghton, D. E. (2025) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2025.102878 · Cited by 5
“…- 1 of 9 https://doi.org/10.1016/j.rpth.2025.102878 Reduced or low-dose direct oral anticoagulants (DOACs) have been studied in randomized controlled trials (RCTs) for the extended prevention of venous thromboembolism (VTE) after at least 6 months of treatment at standard therapeutic doses [1 – 3].”
InfluentialAmado, V. M., Fernandes, C. J. C. D. S., Salibe-Filho, W., Gazzana, M. B., Rocha, A. T., Yoo, H. H. B., Bernardo, W. M., & Tanni, S. É. (2025) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20240314 · Cited by 5
“(16,40) Periodic reassessment of patients regarding the risk of bleeding during anticoagulation should be conducted using scales specifically designed for this purpose.”
InfluentialPoli, D., Parisi, R., Antonucci, E., Barcella, L., Bucherini, E., Chistolini, A., Giorgio, A. D., Giulio, R. D., Nisio, M. D., Elmi, G., et al. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.07.034 · Cited by 5
Akhtar, M., Nabi, R., Saadia, S., Ashraf, D. A., Hassan, S. M., Akhtar, M., Zia, M. A., & Ahmed, R. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07759-1 · Cited by 5
Ibrahim, A. M., Shalabi, L., Zreigh, S., Tawfik, A. M., Hamed, B. M., Elsawy, M., Pathak, A., Mamas, M. A., Andò, G., Elgendy, I. Y., et al. (2025) · Thrombosis Research · doi:10.1016/j.thromres.2025.109476 · Cited by 5
Inconsistencies in reporting of renal elimination among NOACs: the case of apixaban
Hellfritzsch, M., Damkier, P., Pottegård, A., Grønlykke, T. B., & Grove, E. L. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3916 · Cited by 5
Guercini, F., Mommi, V., Camporese, G., Tonello, C., Imberti, D., Benedetti, R., Bartolomeo, G. D., Lecce, L. D., Romeo, F., & Agnelli, G. (2016) · Internal and Emergency Medicine · doi:10.1007/s11739-016-1507-6 · Cited by 5
Self-citationSafety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism
Imberti, D., Pomero, F., Benedetti, R., & Fenoglio, L. M. (2016) · Internal and Emergency Medicine · doi:10.1007/s11739-016-1521-8 · Cited by 6
Li, D., Liu, Y., Song, Y. H., & Wen, A. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2026002 · Cited by 5
“[44,45] AMPLIFY-EXT study evaluated the effect of lowapixaban, apixaban versus placebo, and demonstrated that both dose of apixaban were superior to placebo on recurrent VTE [23].”
MethodAntithrombotika und Antihämorrhagika
Hein, L., & Wille, H. (2016) · Springer eBooks · doi:10.1007/978-3-662-50351-5_18 · Cited by 5
Hosokawa, K., Abe, K., Kishimoto, J., Kobayakawa, Y., Todaka, K., Tamura, Y., Tatsumi, K., Inami, T., Ikeda, N., Taniguchi, Y., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061225 · Cited by 5
Chistolini, A., Serrao, A., Assanto, G. M., Genoese, A., Baldacci, E., Ligia, S., Breccia, M., & Santoro, C. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05369-1 · Cited by 5
Cancer-Associated Thrombosis: Management of a Patient With an Isolated Calf Deep Vein Thrombosis
Soff, G. A. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01905 · Cited by 5
Laganà, A., Assanto, G. M., Masucci, C., Passucci, M., Donzelli, L., Serrao, A., Baldacci, E., Santoro, C., & Chistolini, A. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2024.020 · Cited by 6
“Hence, our objective was to provide data on long-term low-intensity DOAC efficacy and safety, which are lacking in pivotal studies such as the AMPLIFY-EXT trial 9 and the EINSTEIN-CHOICE trial.”
BackgroundInfluentialAnticoagulation Management Post Pulmonary Embolism
Naoum, J. J. (2024) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1338 · Cited by 9
Hale, G. M., & Brenner, M. J. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0122-7 · Cited by 5
“AMPLIFY-EXT showed apixaban was superior to placebo in recurrent VTE or all-cause death [52].”
BackgroundMethodWhat are the pharmacotherapy options for treating venous thromboembolism in cancer patients?
Prandoni, P., Piovella, C., Filippi, L., Vedovetto, V., Valle, F. D., & Piccioli, A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.889685 · Cited by 6
Conventional and New Oral Anticoagulants in the Treatment of Chest Disease and its Complications
Gallego, P., Roldán, V., & Lip, G. Y. H. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201301-0141pp · Cited by 5
“anticoagulation therapy for additional 12 months beyond the initial 6 month treatment) [31].”
BackgroundThe New Era of Anticoagulation
Skeik, N., Rumery, K. K., & Rodriguez, G. T. (2013) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2013.07.013 · Cited by 8
Akwaa, F., & Spyropoulos, A. C. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.951425 · Cited by 5
Using New Oral Anticoagulants in Patients Undergoing Major Orthopedic Surgery
Bass, A. R. (2015) · Current Rheumatology Reports · doi:10.1007/s11926-015-0498-z · Cited by 5
Duration of Anticoagulation for Venous Thromboembolic Events
Smilowitz, N. R., Mega, J. L., & Berger, J. S. (2014) · Circulation · doi:10.1161/circulationaha.114.010456 · Cited by 6
“Remarkably, clinically relevant bleeding was not significantly more common in patients randomized to either dose of apixaban compared with placebo.(11) The Once-Daily Oral Direct Factor Xa Inhibitor Rivaroxaban in the Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Dee…”
BackgroundEconomic Implications of Inadequate Treatment of Venous Thromboembolism and Potential Solutions
Dobesh, P. P. (2013) · Journal of Pharmacy Practice · doi:10.1177/0897190013513802 · Cited by 5
ten Cate‐Hoek, A. J., Weitz, J. I., Gailani, D., Meijer, K., Philippou, H., Bouman, A. C., Cheung, Y. W., van Mens, T. E., Govers‐Riemslag, J. W. P., Vries, M. J. A., et al. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.07.036 · Cited by 5
“Although rates of major bleeding were low, there was a trend for less clinically relevant non-major bleeding with the lower dose regimen [2].”
BackgroundSelf-citationGranziera, S., Hasan, A., & Cohen, A. T. (2015) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029615600791 · Cited by 7
“The principal safety outcome varied between studies and was defined as major bleeding (according to the International Society on Thrombosis and Haemostasis definition) in AMPLIFY8 and clinically relevant bleeding (composite of major and nonmajor clinically relevant bleeding) in EINSTEIN DVT, EINSTEIN PE,10,11 and Hoku…”
BackgroundResultInfluentialSelf-citationApixaban in the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation
Pujadas-Mestres, L., Escolar, G., Arellano‐Rodrigo, E., & Galan, A. M. (2013) · Drugs of today · doi:10.1358/dot.2013.49.7.1980498 · Cited by 5
Safety of non-vitamin K antagonist oral anticoagulants - coronary risks
Caldeira, D., Ferreira, J. J., Pinto, F. J., & Costa, J. N. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1164689 · Cited by 6
Wong, W. H., Yip, C. Y. C., Sum, C. L. L., Tan, C. W., Lee, L. H., Yap, E. S., Kuperan, P., Ting, W. C., & Ng, H. J. (2016) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v45n3p98 · Cited by 5
Apixaban Interacts with Haemoglobin: Effects on Its Plasma Levels
Sacco, M., Lancellotti, S., Berruti, F., Arcovito, A., Bellelli, A., Ricciardelli, T., Autiero, I., Cavallo, L., Oliva, R., & CRISTOFARO, R. D. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1669920 · Cited by 6
Quelle est la durée du traitement anticoagulant pour une EP/TVP proximale ?
Couturaud, F., Girard, P., Laporte, S., & Sanchez, O. (2019) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2019.05.022 · Cited by 5
Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice
Hendriks, S. V., Klok, F. A., Stenger, W. J. E., Mairuhu, A. T. A., Eikenboom, J. C. J., Fogteloo, J., & Huisman, M. V. (2020) · TH Open · doi:10.1055/s-0040-1713683 · Cited by 5
Hoffmann, C., Leven, C., Mao, R. L., MOREUIL, C. D., & Lacut, K. (2020) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2020.05.026 · Cited by 10
Wang, J., Lim, H. Y., & Ho, P. W. (2021) · Hemato · doi:10.3390/hemato2010003 · Cited by 7
MacLehose, R. F., Zakai, N. A., Walker, R. F., Alonso, Á., Adams, T., & Lutsey, P. L. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12514 · Cited by 5
Singh, S., Singh, J., Sethi, S., Kaur, T., Bhardwaj, A., Meena, M. K., & Singla, M. (2021) · International Journal of Applied and Basic Medical Research · doi:10.4103/ijabmr.ijabmr_135_21 · Cited by 5
Scott, L. C., Li, J., Cafuir, L. A., Gaddh, M., & Kempton, C. L. (2022) · eJHaem · doi:10.1002/jha2.418 · Cited by 5
Pon, G., Pelsue, B., Reddy, S. T., Parsha, K., Zhang, X., Gulbis, B. E., Barreto, A. D., Savitz, S. I., Escobar, M. A., & Allison, T. A. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.06.021 · Cited by 5
Wilson, M. R., & Tait, R. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386882-4.00023-2 · Cited by 5
Deep Vein Thrombosis – Current Management Strategies
Endig, H., Michalski, F., & Beyer‐Westendorf, J. (2016) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s18890 · Cited by 7
Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: who, where and for how long?
Howard, L. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2018.1452614 · Cited by 5
“Overall, the composite of major and clinically relevant nonmajor bleeding was low and similar to placebo with no statistically significant difference between the two doses of apixaban, although numerically there were fewer bleeding events with the lower of the two doses [19].”
BackgroundResultVariability in the management of line-related upper extremity deep vein thrombosis
Cires-Drouet, R. S., Sharma, J., McDonald, T., Sorkin, J. D., & Lal, B. K. (2019) · Phlebology The Journal of Venous Disease · doi:10.1177/0268355519827155 · Cited by 5
Lobastov, K. V. (2019) · Pirogov Russian Journal of Surgery · doi:10.17116/hirurgia201905194 · Cited by 5
Pharmacokinetics and Pharmacogenetics of Apixaban
Savinova, A. V., Петрова, М. М., Shnayder, N. A., Николаевна, Б. Е., & Nasyrova, R. F. (2020) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2020-10-17 · Cited by 5
Gallo, A., Valerio, L., & Barco, S. (2021) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytaa542 · Cited by 5
Ma, T., Liu, C., Jiang, T., Qin, H., Wu, R., & Zhou, P. (2021) · Medicine · doi:10.1097/md.0000000000024522 · Cited by 5
“5mg twice daily 67 0 2 1528 Yes 60d Enoxaparin 40mg once daily 67 0 0 1529 Agnelli G AMPLIFY-EXT([9]) 2013 Venous thromboembolism Apixaban 2.”
BackgroundManagement of Patients With Venous Thromboembolism After the Initial Treatment Period
Fernandes, T. M., Kanwar, M. K., & White, R. (2021) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2021.02.200085 · Cited by 6
Shaydakov, M. E., Ting, W., Sadek, M., Aziz, F., Diaz, J. A., Comerota, A. J., Lurie, F., Blebea, J., Eklöf, B., Lugli, M., et al. (2022) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2022.03.013 · Cited by 6
Jeelani, H. M., Sheikh, M. M., Tahir, N., Ying, G. W., Prasad, S., Yaremko, M., & Gill, J. (2022) · JACC Case Reports · doi:10.1016/j.jaccas.2022.01.027 · Cited by 5
“The use of direct oral anticoagulants (DOACs) is recommended in such patients.(8) However, interestingly, both ibrutinib and DOACs are metabolized by the cytochrome P450 (CYP) 3A4 system, and co-administration leads to further drug-drug interaction, resulting in enhanced ibrutinib toxicity and bleeding risk by decreas…”
BackgroundCurrent Management of Pulmonary Thromboembolism
Kim, Y. (2013) · Korean Journal of Medicine · doi:10.3904/kjm.2013.84.5.659 · Cited by 6
“재발의 고위험군을 대상으로 급성기 치료 후 6개월 이상 연장치료(extended therapy)를 시행하여 그 치료 효과 및 안전 성을 보고하였다[23,25,26].”
Spotlight on real-world evidence for the treatment of DVT: XALIA
Turpie, A. G. G., & Ageno, W. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-06-0488 · Cited by 5
“NOACs have been evaluated for the secondary prevention of recurrent VTE and appear to be effective agents in this setting, with an acceptable risk of bleeding (12, 48, 49), although further data are warranted to provide comprehensive evidence on optimal treatment duration in everyday clinical practice.”
BackgroundAnticoagulant therapy in the elderly
Karetová, D., & Bultas, J. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.146 · Cited by 5
Gary, T. (2019) · Learning materials in biosciences · doi:10.1007/978-3-030-12270-6_11 · Cited by 5
Palareti, G., Antonucci, E., Ageno, W., Mastroiacovo, D., Poli, D., & Tosetto, A. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14300 · Cited by 5
The Newer Anticoagulants in Thrombosis Control in Cancer Patients
den Exter, P. L., van der Hulle, T., Klok, F. A., & Huisman, M. V. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.04.014 · Cited by 4
Major acute cardiovascular events after venous thromboembolism: a meta-analysis of randomized trials
Becattini, C., & Vedovati, M. C. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.02.023 · Cited by 4
Venöse Thromboembolie – was ist neu in der aktualisierten AWMF-Leitlinie?
Linnemann, B., Mühlberg, K. S., & Klamroth, R. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2128-0005 · Cited by 4
Vichaidit, K., Chantrathammachart, P., Niparuck, P., Puavilai, T., Angchaisuksiri, P., & Boonyawat, K. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102643 · Cited by 4
“Studies on unprovoked VTE have shown that reduced-dose anticoagulants after completion of 6 to 12 months of a therapeutic dose of DOACs were not associated with any difference in the risk of recurrent thrombosis or major bleeding when compared with the full-therapeutic doses [4,5].”
Hosokawa, K., & Abe, K. (2025) · Journal of Cardiology · doi:10.1016/j.jjcc.2025.03.006 · Cited by 7
Mahmoud, A. A., Eltaher, B., Shah, P., Vengilote, R., Mostafa, M. A. O., Afzal, A., & Sanfilippo, K. M. (2025) · American Journal of Hematology · doi:10.1002/ajh.70090 · Cited by 4
“Our results are consistent with prior trials in noncancer patients that have also shown numerically lower risk of clinically relevant bleeding with a reduced dose of DOACs [13, 14, 16].”
Lin, K. J., Kim, D., Singer, D. E., Zhang, Y., Cervone, A., Kehoe, A. R., & Bykov, K. (2025) · BMJ · doi:10.1136/bmj-2025-084380 · Cited by 5
Emergency Reversal of Antithrombotics in Intracerebral Hemorrhage: An Update
Li, M., & Frontera, J. A. (2025) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-025-01469-9 · Cited by 4
Nicoletto, M., Maino, A., Guarascio, M., Cavalleri, M., Gallucci, F., Dentali, F., & Pomero, F. (2026) · Thrombosis Research · doi:10.1016/j.thromres.2026.109669 · Cited by 4
Direct Oral Anticoagulants in Antiphospholipid Syndrome: Too Early or Too Late?
Wahl, D. G., & Dufrost, V. (2019) · Annals of Internal Medicine · doi:10.7326/m19-2815 · Cited by 5
“Should other DOAC treatment strategies be considered? Apixaban, another factor Xa inhibitor, has been used in VTE in the general population, and a reduced dose has been shown to be an effective and safe alternative to a conventional regimen for long-term secondary prophylaxis (7).”
BackgroundBozkurt, A. K., Akay, H. T., Çalkavur, T., Şırlak, M., Balkanay, O. O., Uğuz, E., Doğancı, S., Polat, A., Bayrak, S., Bozok, Ş., et al. (2021) · Turkish Journal of Thoracic and Cardiovascular Surgery · doi:10.5606/tgkdc.dergisi.2021.22121 · Cited by 6
“However, researches are ongoing due to the high risk of rethrombosis.[32-37] In comparative studies with DOACs, 2.”
BackgroundAntithrombotika und Antihämorrhagika
Hein, L., & Wille, H. (2020) · Springer eBooks · doi:10.1007/978-3-662-62168-4_16 · Cited by 6
Groat, D., Martin, K. A., Rosovsky, R. P. G., Sanfilippo, K. M., Gaddh, M., Kreuziger, L. B., Eyster, M. E., & Woller, S. C. (2022) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12740 · Cited by 4
Liu, M., Qiu, X., Sun, Y., Li, Q., Wen, J., Liu, G., Yao, Z., & Zhu, L. Y. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.09.014 · Cited by 4
Camporese, G., Bernardi, E., Bortoluzzi, C., Noventa, F., Simioni, P., & for the METRO Investigator Study Group (2023) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-023-02896-6 · Cited by 4
Apixaban plasma concentrations in patients with obesity
Al-Aieshy, F., Skeppholm, M., Fyrestam, J., Johansson, F., Pohanka, A., & Malmström, R. E. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03696-4 · Cited by 5
“There are scarce data on high body weight in the pivotal clinical trials for apixaban; in some trials, safety/ efficacy analyses on patients with high body weight were not presented (AVERROES, AMPLIFY EXT) [17, 18].”
BackgroundAnticoagulant therapy in renal insufficiency theme: Anticoagulation in complex situations
Parks, A. L., Stevens, S. M., & Woller, S. C. (2024) · Thrombosis Research · doi:10.1016/j.thromres.2024.109097 · Cited by 4
Laganà, A., Sorella, S., Fucci, L., Santoro, C., Ligia, S., Mormile, R., Baldacci, E., & Chistolini, A. (2024) · Annals of Hematology · doi:10.1007/s00277-024-06021-2 · Cited by 4
“Nevertheless, patients with major thrombophilia represented just the 3.8% of the apixaban 2.5 mg BID group in the AMPLIFY-EXT trial [10] and the 6.6% of the rivaroxaban 10 mg daily group in the EINSTEIN-CHOICE trial [11].”
InfluentialMithoowani, S., Bungard, T. J., Castellucci, L. A., Crowther, M., de Wit, K., Dowlatshahi, D., Forbes, N., Lin, K. Y., & Siegal, D. M. (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2464-2887 · Cited by 8
Boccatonda, A., Simion, C., Brighenti, A., Serra, C., Simioni, P., & Campello, E. (2025) · Thrombosis Research · doi:10.1016/j.thromres.2025.109403 · Cited by 4
The history and historical treatments of deep vein thrombosis: toward the era of new anticoagulants
Galanaud, J. ‐., Laroche, J.-P., & Righini, M. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.07.019 · Cited by 5
Ahmed, M., Zulfiqar, E., Ashraf, H., Hashmi, T. M., Ahmed, R., Rana, J. S., Greene, S. J., Mentz, R. J., Fudim, M., & Fonarow, G. C. (2025) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2025.102996 · Cited by 4
“…Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism (EINSTEIN CHOICE), have assessed the efficacy and safety of reduced-dose DOACs such as apixaban and rivaroxaban, demonstrating their ability to prevent VTE recurrence with a lower risk of bleeding [9,10].”
InfluentialLingohr, A. A. M. (2015) · Journal of Hematology & Thromboembolic Diseases · doi:10.4172/2329-8790.1000209 · Cited by 4
“The clinical event rates were estimated from the published data of the clinical trials, RE-SONATE, EINSTEN-EXT, and AMPLIFY-EXT as done for prior analyses [24,46,47].”
MethodBon usage d’apixaban : que retenir pour la pratique
Albaladejo, P., Deplanque, D., Fossati, F., Mahagne, M., Mismetti, P., Nguyên, P., Roy, P., Touzé, E., & Mourad, J. (2014) · Journal des Maladies Vasculaires · doi:10.1016/j.jmv.2014.09.002 · Cited by 4
“L’étude AMPLIFY-EXT [7] a confirmé l’intérêt de la poursuite de l’apixaban sur une période additionnelle d’un an dans le traitement de la MTEV.”
Meddahi, S., & Samama, M. M. (2014) · Journal des Maladies Vasculaires · doi:10.1016/j.jmv.2014.02.001 · Cited by 4
Aziz, F., & Comerota, A. J. (2013) · Journal of Radiology Nursing · doi:10.1016/j.jradnu.2013.06.001 · Cited by 4
New oral anticoagulants: An emergency department overview
Wood, P. (2013) · Emergency Medicine Australasia · doi:10.1111/1742-6723.12156 · Cited by 4
Practical Management of Rivaroxaban for the Treatment of Venous Thromboembolism
Imberti, D., & Benedetti, R. (2013) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029613503397 · Cited by 4
Initial and Long-Term Treatment of Pulmonary Embolism: Current Approach and Future Perspectives
Ageno, W., & Donadini, M. P. (2018) · Hämostaseologie · doi:10.1055/s-0038-1641605 · Cited by 4
Kanaan, D. M., Cook, B. M., Kelly, J., & Malloy, R. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.04.009 · Cited by 4
Palareti, G., Legnani, C., Poli, D., Ageno, W., Pengo, V., Testa, S., Tosetto, A., & Prandoni, P. (2022) · Haematologica · doi:10.3324/haematol.2022.282130 · Cited by 4
Zbinden, S., Voci, D., Grigorean, A., Holy, E. W., Kaufmann, P. A., Münger, M., Pleming, W., Kucher, N., & Barco, S. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.03.014 · Cited by 4
Screening Feature Genes of Venous Thromboembolism with DNA Microarray
Zhou, T., Zhang, Y., Wu, P., Sun, Q., & Guo, Y. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12557 · Cited by 7
“Moreover, drugs in anticoagulant therapy is commonly used for VTE treatment, such as aspirin (5) and apixaban (6).”
BackgroundWojtukiewicz, M. Z., Sierko, E., Tomkowski, W. Z., Zawilska, K., Undas, A., Podolak‐Dawidziak, M., Wysocki, P. J., Krzakowski, M. J., Warzocha, K., & Windyga, J. (2016) · Nowotwory Journal of Oncology · doi:10.5603/njo.2016.0062 · Cited by 8
Nuevos anticoagulantes orales: actualización
Berkovits, A., & Mezzano, D. (2017) · Revista chilena de cardiología · doi:10.4067/s0718-85602017000300254 · Cited by 11
Controversies in anticoagulation therapy in patients with cirrhosis
Sasso, R., & Rockey, D. C. (2019) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000523 · Cited by 4
Mahat, U., Ahuja, S. P., & Talati, R. (2020) · Progress in Pediatric Cardiology · doi:10.1016/j.ppedcard.2019.101190 · Cited by 4
Metadata
- Authors
- Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I.
- Affiliations
- University of Perugia (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- King's College Hospital (GB)
- McMaster University (CA)
- Flinders University (AU)
- University of Oklahoma Health Sciences Center (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-21
- Volume
- 368
- Issue
- 8
- Pages
- 699-708
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139785591
- Cited by
- 1,366
- References
- 19
- Citations by year
- 2026: 70 · 2025: 80 · 2024: 64 · 2023: 68 · 2022: 90 · 2021: 98 · 2020: 101 · 2019: 114 · 2018: 103 · 2017: 89 · 2016: 109 · 2015: 133 · 2014: 141 · 2013: 102
- FWCI
- 81.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Bayer HealthCare
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, venous thromboembolism, long-term anticoagulation, factor Xa inhibitors, recurrent venous thromboembolism, thromboprophylaxis, major bleeding, mortality, dose comparison, oral anticoagulants, clinical equipoise, post-thrombotic syndrome, pulmonary embolism, deep vein thrombosis
- MeSH terms
- Adult, Aged, Creatinine, Double-Blind Method, Female, Fibrinolytic Agents, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Recurrence, Treatment Outcome, Kaplan-Meier Estimate, Venous Thromboembolism, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.